<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164787</url>
  </required_header>
  <id_info>
    <org_study_id>CL-028-TRAN-2006</org_study_id>
    <nct_id>NCT01164787</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Comparative Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited and Mavik® 4 mg Tablets of Abbott Laboratories, in Healthy, Adult, Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is

        -  To compare the single oral dose bioavailability of test product, Trandolapril 4 mg
           Tablets of Dr. Reddy's and Mavik® 4 mg Tablet of Abbott Laboratories, in healthy, adult,
           human subjects, under fed conditions to assess bioequivalence.

        -  To monitor adverse events and ensure safety of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, randomised, two-treatment, two-sequence, two-period, two-way
      cross-over,single-dose bioequivalence study of Trandolapril4 mg Tablets manufactured by Dr.
      Reddy's Laboratories Ltd., Generics, India comparing with the Mavik® 4 mg Tablets (containing
      trandolapril 4 mg) manufactured by Abbott Laboratories, North Chicago, IL 60064, US; in
      healthy, adult, human subjects under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">April 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence is based on Cmax and AUC parameters.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Trandolapril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mavik®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mavik® 4 mg Tablets of Abbott Laboratories, USA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trandolapril</intervention_name>
    <description>Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Trandolapril</arm_group_label>
    <other_name>Mavik® 4 mg Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mavik</intervention_name>
    <description>Mavik® 4 mg Tablets of Abbott Laboratories, USA.</description>
    <arm_group_label>Mavik®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy human subjects within the age range of 18 to 45 years

          -  Non-smokers since at least six months

          -  Willingness to provide written informed consent to participate in the study

          -  Body-mass index of ≥ 18.5 kg/m2 and ≤24.9 kg/m2, with body weight not less than 50 kg

          -  Absence of significant disease or clinically significant abnormal laboratory values on
             laboratory evaluations, medical history or physical examination during the screening
             Normal 12-lead ECG or one with abnormality considered to be clinically insignificant
             Normal chest X-ray PA view Comprehension of the nature and purpose of the study and
             compliance with the requirement of the Protocol

          -  Female Subjects

               -  of child bearing potential practicing an acceptable method of birth control for
                  the duration of the study as judged by the investigator(s), such as condoms,
                  foams, jellies, diaphragm,intrauterine device (IUD), or abstinence, or

               -  postmenopausal for at least 1 year, or

               -  surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy has been performed on the subject

        Exclusion Criteria:

          -  Personal/family history of allergy or hypersensitivity to Trandolapril or allied drugs

          -  Past history of anaphylaxis or angioedema

          -  Any major illness in the past three months or any clinically significant ongoing
             chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.

          -  Presence of any clinically significCint abnormal values during screening e.g.
             significant abnormality of Liver Function Test (LFT), Renal (kidney) Function Test
             (RFT), etc.

          -  Any cardiac, renal or liver impairment, any other organ or system impairment

          -  History of seizure or psychiatric disorders

          -  Presence of disease markers of HIV 1 and 2, and hepatitis B and C virus

          -  Consumption of alcohol for more than two years, or consumption of more than three
             alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and
             during the study [one drink is equal to one unit of alcohol [one glass wine, half pint
             beer, and one measure (one ounce) of spirit).

          -  Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate)
             within 48 hours before check-in of each period

          -  Use of any recreational drug or a history of drug addiction

          -  Participation in any clinical trial within the past 3 months

          -  Inaccessibility of veins in left and right arm

          -  Donation of blood (one unit or 350 mL) within 3 months prior to receiVing the first
             dose of study medication

          -  Regular smoker who has a habit of smoking more than nine cigarettes per day and has
             difficulty in abstaining from smoking from 48 hours before dosing and until the
             completion of the study.

          -  Receipt of any prescription drug therapy within four weeks or over-the-counter (OTC)
             drugs within two weeks prior to receiving the first dose of study medication or
             repeated use of drugs within the last four weeks

          -  An unusual diet, for whatever reason e.g. low sodium diet, for two weeks prior to
             receiving any medication and through out subject's participation in the study

          -  Consumption of grapefruit- containing food or beverages within 10 days prior to
             receiving the first dose of study medication in both the periods

          -  Recent history of dehydration from diarrhoea, vomiting or any other reason within a
             period of 24 hours prior to the study

          -  Female subjects who are pregnant or who are able (women with child bearing potential)
             to become pregnant during the study will not be allowed to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Umesh Dhakate, M.B.B.S</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wellquest Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wellquest Clinical Research</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2010</study_first_posted>
  <last_update_submitted>July 16, 2010</last_update_submitted>
  <last_update_submitted_qc>July 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. M.S. Mohan/ Vice President R &amp; D</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Crossover</keyword>
  <keyword>Trandolapril</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trandolapril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

